Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057941 · ClinicalTrials.gov registry record · Phase 2
Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 148
- Enrollment target
NCT00057941: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00057941 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 148 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00057941, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 148 participants
- Enrollment target
Study Summary
This randomized phase II trial is studying how well giving gefitinib together with anastrozole works compared to giving gefitinib together with fulvestrant in treating postmenopausal women with recurrent or metastatic breast cancer. Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using anastrozole and fulvestrant may fight breast cancer by blocking the use of estrogen. Gefitinib (ZD1839) may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It is not yet known whether gefitinib is more effective when combined with anastrozole or fulvestrant in treating breast cancer.
Interventions
- OTHER laboratory biomarker analysis
- DRUG fulvestrant
- DRUG anastrozole
- DRUG gefitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2003-09 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00057941
The ClinicalTrials.gov registry entry for NCT00057941 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00057941 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00057941 about?
NCT00057941 is a clinical study titled "Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer". This randomized phase II trial is studying how well giving gefitinib together with anastrozole works compared to giving gefitinib together with fulvestrant in treating postmenopausal women with recurrent or metastatic breast cancer. Estrogen can stimulate the growth of breast cancer cells. Hormone t...
What is the current status of trial NCT00057941?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 148 participants. The study started on 2003-09. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00057941?
The interventions under investigation include: laboratory biomarker analysis (OTHER), fulvestrant (DRUG), anastrozole (DRUG), gefitinib (DRUG).
Who is sponsoring clinical trial NCT00057941?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.